Evolent Health, Inc Class A Common Stock
Here’s whether Evolent Health, Inc Class A Common Stock (EVH) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: trading above the 200-day MA (long-term uptrend intact); 3-month momentum positive (+18.2%). Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-0.23% over 10 days); weak 1-year return of -46.9%. Currently 53.6% off its 52-week high. Score: +0/7.
EVH is holding above its long-term 200-day MA ($3.94) but has slipped below the 50-day MA ($4.75), pointing to short-term weakness in an otherwise intact trend. An RSI of 67.6 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -46.9% compares to +20.4% for SPY (trailed the market by 67.3%). The current 53.6% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.